Cargando…

Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study

Background: Patients with inflammatory bowel disease (IBD) and symptoms of irritable bowel syndrome (IBS) may be intolerant to fermentable carbohydrates (FODMAPs). The aim of this study was to test the feasibility of eliminating and subsequently reintroducing FODMAPs in patients with IBS symptoms as...

Descripción completa

Detalles Bibliográficos
Autores principales: Melgaard, Dorte, Sørensen, Jeanette, Riis, Johannes, Ovesen, Tine S., Leutscher, Peter, Sørensen, Suzette, Knudsen, Julie K., Bundgaard-Nielsen, Caspar, Ejstrup, Jeanette, Jensen, Ann-Maria, Borre, Mette, Krarup, Anne L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955641/
https://www.ncbi.nlm.nih.gov/pubmed/35334953
http://dx.doi.org/10.3390/nu14061296
_version_ 1784676385958133760
author Melgaard, Dorte
Sørensen, Jeanette
Riis, Johannes
Ovesen, Tine S.
Leutscher, Peter
Sørensen, Suzette
Knudsen, Julie K.
Bundgaard-Nielsen, Caspar
Ejstrup, Jeanette
Jensen, Ann-Maria
Borre, Mette
Krarup, Anne L.
author_facet Melgaard, Dorte
Sørensen, Jeanette
Riis, Johannes
Ovesen, Tine S.
Leutscher, Peter
Sørensen, Suzette
Knudsen, Julie K.
Bundgaard-Nielsen, Caspar
Ejstrup, Jeanette
Jensen, Ann-Maria
Borre, Mette
Krarup, Anne L.
author_sort Melgaard, Dorte
collection PubMed
description Background: Patients with inflammatory bowel disease (IBD) and symptoms of irritable bowel syndrome (IBS) may be intolerant to fermentable carbohydrates (FODMAPs). The aim of this study was to test the feasibility of eliminating and subsequently reintroducing FODMAPs in patients with IBS symptoms as part of the IBD manifestation and to compare the severity of IBS symptoms and pain, bloating and quality of life (QoL). Methods: An eight-week randomised open-label FODMAP elimination with double-blinded, crossover provocations of FODMAP and placebo. Diet patients were on a low-FODMAP diet for eight weeks with blinded two-week provocations after two and six weeks. Questionnaires, blood and stool samples were collected. Results: Patient enrolment was challenging. Nineteen participants were included in the study. Eliminating low FODMAP for two weeks resulted in significant decreases in pain and bloating scores (p < 0.003), whereas there were no statistical differences in pain scores between diet patients and controls. Pain and bloating scores increased, returning to baseline levels after two weeks of double-blinded provocations with placebo, (p > 0.05). Conclusions: The results document the possibility of performing a randomised controlled study following the gold standard for testing food intolerance with blinding of the Low FODMAP diet. Recruitment of participants was challenging.
format Online
Article
Text
id pubmed-8955641
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89556412022-03-26 Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study Melgaard, Dorte Sørensen, Jeanette Riis, Johannes Ovesen, Tine S. Leutscher, Peter Sørensen, Suzette Knudsen, Julie K. Bundgaard-Nielsen, Caspar Ejstrup, Jeanette Jensen, Ann-Maria Borre, Mette Krarup, Anne L. Nutrients Article Background: Patients with inflammatory bowel disease (IBD) and symptoms of irritable bowel syndrome (IBS) may be intolerant to fermentable carbohydrates (FODMAPs). The aim of this study was to test the feasibility of eliminating and subsequently reintroducing FODMAPs in patients with IBS symptoms as part of the IBD manifestation and to compare the severity of IBS symptoms and pain, bloating and quality of life (QoL). Methods: An eight-week randomised open-label FODMAP elimination with double-blinded, crossover provocations of FODMAP and placebo. Diet patients were on a low-FODMAP diet for eight weeks with blinded two-week provocations after two and six weeks. Questionnaires, blood and stool samples were collected. Results: Patient enrolment was challenging. Nineteen participants were included in the study. Eliminating low FODMAP for two weeks resulted in significant decreases in pain and bloating scores (p < 0.003), whereas there were no statistical differences in pain scores between diet patients and controls. Pain and bloating scores increased, returning to baseline levels after two weeks of double-blinded provocations with placebo, (p > 0.05). Conclusions: The results document the possibility of performing a randomised controlled study following the gold standard for testing food intolerance with blinding of the Low FODMAP diet. Recruitment of participants was challenging. MDPI 2022-03-18 /pmc/articles/PMC8955641/ /pubmed/35334953 http://dx.doi.org/10.3390/nu14061296 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Melgaard, Dorte
Sørensen, Jeanette
Riis, Johannes
Ovesen, Tine S.
Leutscher, Peter
Sørensen, Suzette
Knudsen, Julie K.
Bundgaard-Nielsen, Caspar
Ejstrup, Jeanette
Jensen, Ann-Maria
Borre, Mette
Krarup, Anne L.
Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study
title Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study
title_full Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study
title_fullStr Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study
title_full_unstemmed Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study
title_short Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study
title_sort efficacy of fodmap elimination and subsequent blinded placebo-controlled provocations in a randomised controlled study in patients with ulcerative colitis in remission and symptoms of irritable bowel syndrome: a feasibility study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955641/
https://www.ncbi.nlm.nih.gov/pubmed/35334953
http://dx.doi.org/10.3390/nu14061296
work_keys_str_mv AT melgaarddorte efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy
AT sørensenjeanette efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy
AT riisjohannes efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy
AT ovesentines efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy
AT leutscherpeter efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy
AT sørensensuzette efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy
AT knudsenjuliek efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy
AT bundgaardnielsencaspar efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy
AT ejstrupjeanette efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy
AT jensenannmaria efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy
AT borremette efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy
AT krarupannel efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy